Ischemia  >>  atopaxar (E5555)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
atopaxar (E5555) / Eisai
NCT00312052 / 2005-006029-94: Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

Completed
2
720
US
E5555, Placebo
Eisai Inc.
Coronary Artery Disease
03/08
08/09
NCT00540670: A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

Completed
2
240
Japan
E5555 50 mg, E5555 100 mg, E5555 200 mg, Placebo
Eisai Co., Ltd.
Coronary Artery Disease
03/09
 
NCT00548587 / 2006-000296-15: Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

Completed
2
600
US, Europe
E5555, Placebo
Eisai Inc.
Acute Coronary Syndrome
04/09
08/09
NCT00619164: A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome

Completed
2
240
Japan
E5555, Placebo
Eisai Co., Ltd.
Acute Coronary Syndrome
09/09
 

Download Options